Peptide Hormone Receptors — Class B GPCRs

Executive Summary

Class B (secretin-like) G protein-coupled receptors mediate the physiological actions of a distinct group of structurally related peptide hormones that regulate metabolic homeostasis, stress responses, calcium balance, and gastrointestinal function. This receptor family, comprising 15 members in humans, includes some of the most clinically important drug targets of the 21st century: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR), all of which are central to the regulation of glucose metabolism and energy balance. The therapeutic targeting of these receptors has produced transformative drugs for type 2 diabetes and obesity, most notably the GLP-1 receptor agonists semaglutide, liraglutide, and dulaglutide, and the dual GLP-1/GIP receptor co-agonist tirzepatide. This article provides a comprehensive examination of the structural architecture of class B GPCRs—the distinctive two-domain organization comprising a large N-terminal extracellular domain (ECD) and a seven-transmembrane domain (TMD); the molecular mechanism of peptide recognition through the two-domain binding model; the structural basis of biased agonism at class B receptors; the detailed pharmacology of the GLP-1 receptor as a paradigm for class B receptor drug discovery; the principles of therapeutic peptide design for metabolic class B receptors; and the emerging frontier of multi-receptor co-agonists (GLP-1/GIP/glucagon). With global sales of GLP-1 receptor agonists exceeding $40 billion annually, class B GPCRs represent both a scientific triumph of structure-based drug design and a commercial success story that continues to drive innovation in peptide therapeutics. Researchers can explore peptide resources for class B receptor ligands at RPL Peptide, with supporting characterization data at the RPL Peptide Data Center.

Scientific Summary

Class B GPCRs are the receptors for roughly fifteen peptide hormones — GLP-1, GIP, glucagon, secretin, PTH, calcitonin, and relatives — that control metabolic homeostasis, stress responses, calcium balance, and gastrointestinal function. The topic matters because structure-guided work on this family produced some of the most consequential peptide therapeutics in medicine: long-acting GLP-1 receptor agonists and the multi-receptor co-agonists tirzepatide and retatrutide. Established: the two-domain architecture (a conserved extracellular domain plus a seven-transmembrane domain) and its two-step binding mechanism; GLP-1 physiology including DPP-4-mediated degradation, glucose-dependent insulin secretion, and the chemistry behind once-weekly and orally available agonists; and human outcome evidence for incretin-based therapy, including cardiovascular benefit for liraglutide and superior weight and glycemic effects for dual agonism. Uncertain: how biased signaling maps to clinical differences; the structural basis of bias at class B receptors; the optimal receptor balance in multi-agonists; and whether oral delivery approaches extend beyond the current SNAC-enabled example.

Evidence Overview

Evidence type	What exists — and what does not
Human studies	Extensive for the incretin axis — large randomized programs (LEADER, SURPASS-2, PIONEER, a Phase II retatrutide trial) document glycemic, weight, and cardiovascular outcomes for selected ligands; most other class B receptors have sparse human trial data.
Animal studies	Substantial — rodent and minipig models support pharmacokinetic and metabolic characterization (including semaglutide design); species differences limit direct translation of efficacy and side effects.
In vitro	Established — cAMP, β-arrestin recruitment, and ERK assays in recombinant systems define potency, cooperativity, and apparent bias; assay context influences bias estimates.
Mechanistic	Strong — crystal and cryo-EM structures with mutagenesis define the two-domain binding mechanism and activation of GLP-1R, GIPR, and GCGR; the structural basis of biased signaling remains less resolved.
Preclinical	Broad — dual and triple agonist candidates progress through animal studies before trials; rare or long-term effects cannot be predicted from these models.
Review literature	Extensive — structural, pharmacological, and clinical reviews synthesize class B receptor biology and incretin therapeutic development.

Background

The class B GPCR family was defined through sequence analysis in the 1990s and comprises receptors for the following endogenous peptide hormones: glucagon, GLP-1, GLP-2, GIP, secretin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), growth hormone-releasing hormone (GHRH), corticotropin-releasing factor (CRF, via CRF₁ and CRF₂ receptors), parathyroid hormone (PTH, via PTH1 and PTH2 receptors), calcitonin, and the related calcitonin gene-related peptide (CGRP), adrenomedullin, and amylin receptors. The receptors share approximately 25–50% sequence identity and are unified by their large, structurally conserved N-terminal extracellular domain (ECD) of approximately 120–150 amino acids.

The therapeutic importance of class B GPCRs became apparent with the recognition that GLP-1, a 30-amino-acid incretin hormone released from intestinal L-cells in response to nutrient ingestion, stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner. This glucose dependence—the defining feature of incretin action—means that GLP-1 stimulates insulin secretion only when blood glucose is elevated, eliminating the risk of hypoglycemia that limits the therapeutic window of insulin and sulfonylureas. The subsequent discovery that GLP-1 also suppresses glucagon secretion, slows gastric emptying, and promotes satiety through central nervous system effects identified it as an ideal therapeutic target for type 2 diabetes.

The development of therapeutically viable GLP-1 receptor agonists required overcoming two major obstacles: the extremely short plasma half-life of native GLP-1 (~2 minutes) due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) and renal clearance; and the requirement for injectable administration (as peptides are generally not orally bioavailable). The discovery that exendin-4, a 39-amino-acid peptide from Gila monster venom (Heloderma suspectum), is a potent, long-acting GLP-1R agonist resistant to DPP-4 cleavage provided the first template for therapeutic development. Exenatide (synthetic exendin-4) was approved in 2005 as the first GLP-1R agonist.

Subsequent chemistry efforts produced liraglutide (a GLP-1 analog with a fatty acid side chain that promotes albumin binding, extending half-life to ~13 hours, approved 2010), dulaglutide (a GLP-1–Fc fusion protein for once-weekly dosing, approved 2014), and semaglutide (an optimized GLP-1 analog with enhanced albumin binding and DPP-4 resistance, approved as once-weekly injectable in 2017 and as the first oral GLP-1R agonist in 2019). The most recent innovation, tirzepatide (approved 2022 for type 2 diabetes, 2023 for obesity), is a dual GLP-1/GIP receptor co-agonist that combines incretin receptor activation with an imbalanced signaling profile, achieving superior glycemic control and weight loss compared to selective GLP-1R agonists.

Structural Architecture: ECD + TMD

The Extracellular Domain (ECD)

The class B GPCR ECD is a structurally autonomous domain of approximately 120–150 residues that adopts a characteristic fold stabilized by three conserved disulfide bonds. The core structure, determined first for the PTH1 receptor ECD and subsequently for multiple family members, consists of an N-terminal α-helix, two antiparallel β-sheets arranged in a β-α-β-β-α-β topology, and a C-terminal α-helix. This fold is sometimes described as a sushi domain-like structure, though it is distinct from the CCP (complement control protein) modules that define sushi domains.

The peptide-binding surface of the ECD is formed by the hydrophobic face of the central β-sheet and the flanking loop regions. The C-terminal region of the peptide hormone—which in all class B ligands forms an α-helix in the receptor-bound state—docks into a hydrophobic groove on the ECD. For the GLP-1R ECD, this groove is lined by residues including Leu32, Tyr69, Leu73, Trp87, Tyr88, Leu89, Pro90, Trp91, Arg102, Leu103, and Trp110. The peptide C-terminal α-helix inserts into this groove with the hydrophobic face oriented toward the receptor. The binding interface buries approximately 1,000–1,400 Ų of solvent-accessible surface area, and the affinity of the isolated ECD for the peptide C-terminal fragment is typically in the range of 0.1–1 μM (\(K_d\)), as determined by SPR and ITC.

The ECD plays a critical role beyond simple peptide capture. It contributes to ligand selectivity: the GLP-1R ECD binds GLP-1 with ~10-fold higher affinity than glucagon, and the GCGR ECD shows the reciprocal preference. Mutagenesis and domain-swapping experiments have identified residues in the ECD β-sheet and loop regions that determine this selectivity. The ECD also influences the rate of peptide association (\(k_{on}\)) by capturing and orienting the peptide for productive TMD engagement, and in some receptors (particularly the GCGR), the ECD can modulate basal receptor activity independently of peptide binding.

The Transmembrane Domain (TMD)

The TMD of class B GPCRs adopts the canonical 7TM α-helical fold but with notable differences from class A receptors. The orthosteric binding pocket in the TMD is more open and solvent-exposed than the deeply buried pockets of class A peptide receptors, consistent with the requirement to accommodate the N-terminal region of the peptide hormone that engages the TMD after the C-terminal region has docked onto the ECD.

Key structural features include: (1) an extended extracellular loop 2 (ECL2) that forms a β-hairpin structure over the binding pocket entrance, contributing to peptide recognition and selectivity; (2) a conserved Trp residue at position 4.50 in TM4 that projects into the binding pocket and interacts with the peptide N-terminus; (3) a network of polar residues at the base of the binding pocket (TM2, TM3, TM5, TM6, TM7) that recognizes the peptide N-terminal residues and is critical for receptor activation; and (4) the conserved class B signaling motifs, including the E/DRY analog (an HET motif in TM2) and the PxxG motif in TM6 that functions as a hinge during activation.

The TM6 outward movement during activation—the hallmark of GPCR activation—is conserved in class B receptors but shows class-specific features. In the GLP-1R–G_s complex, TM6 moves outward by approximately 10–12 Å at the cytoplasmic end, similar to the movement observed in class A receptors. However, the pattern of intracellular loop rearrangements differs, reflecting the distinct coupling mechanisms between class B receptors and G proteins. The intracellular loop 2 (ICL2) and helix 8 (H8) contribute more substantially to G protein coupling in class B receptors than in class A receptors.

The Two-Domain Binding Model

Mechanism of Peptide Recognition

Class B GPCR activation by peptide hormones follows a conserved "two-domain" binding mechanism that has been elegantly demonstrated through structural, biochemical, and biophysical studies, culminating in the cryo-EM structures of full-length class B receptors in complex with peptide agonists and G proteins.

Step 1 — ECD Capture (High-Affinity Primary Binding): The C-terminal α-helical region of the peptide hormone (residues ~22–30 for GLP-1, ~30–42 for GIP, ~20–29 for glucagon) binds to the hydrophobic groove on the ECD. This interaction is the primary determinant of binding affinity and occurs with a \(K_d\) of approximately 0.1–1 μM for the isolated ECD. The structure of the GLP-1 C-terminal fragment (residues 15–35) bound to the GLP-1R ECD (PDB: 3IOL) revealed that the peptide forms an α-helix from residues 21–30, with the hydrophobic face (Phe22, Ile23, Trp25, Leu26, Val27) docking into the ECD groove.

Step 2 — TMD Engagement (Low-Affinity Secondary Binding → Activation): The N-terminal region of the peptide (residues 1–10) engages the TMD binding pocket. The affinity of this interaction is substantially lower than ECD binding (\(K_d\) estimated in the μM–mM range) when measured in isolation (i.e., with ECD-deleted receptors). However, the ECD capture step dramatically increases the effective concentration of the peptide N-terminus at the TMD entrance, facilitating productive engagement. The peptide N-terminus inserts into the TMD pocket and makes critical contacts with residues in TM1, TM2, TM3, TM5, TM6, and TM7. These interactions trigger the conformational changes in the TMD that lead to G protein coupling.

In the full-length GLP-1R–GLP-1–G_s complex (PDB: 6B3J), the peptide bridges the ECD and TMD, with the C-terminal helix docked on the ECD and the N-terminus (His7, Ala8, Glu9, Gly10) inserted into the TMD cavity. Critical interactions include hydrogen bonds between His7 (the N-terminal histidine of GLP-1) and residues in TM2 (Arg190^2.60) and TM7 (Gln384^7.49b), and between Glu9 and residues in TM2. The Phe6 residue (substituted for the native Ala6 in some GLP-1 analogs) makes hydrophobic contacts in the TMD core. Mutagenesis studies have confirmed these interactions: mutation of His7 to Ala in GLP-1 reduces agonist potency by >100-fold, and mutation of the corresponding TMD residues in the receptor similarly impairs activation.

Allosteric Coupling Between ECD and TMD

The ECD and TMD are connected by a flexible linker (the "stalk" or "hinge" region) of approximately 10–15 residues that contains a conserved disulfide bond tethering the ECD to ECL1. This linker is not merely a passive connector but actively contributes to the allosteric communication between the two domains. Peptide binding to the ECD induces conformational changes that are transmitted through the stalk to the TMD, priming the receptor for activation. Conversely, TMD conformation influences the peptide-binding properties of the ECD.

The stalk region in different class B receptors adopts distinct conformations that influence the relative orientation of the ECD and TMD. In the GLP-1R, the stalk is relatively short and constrains the ECD in a position that favors peptide capture from the extracellular space. In the GCGR, the stalk is longer and more flexible, allowing the ECD to adopt conformations that regulate basal receptor activity. A naturally occurring missense mutation in the GCGR stalk region (Gly40Ser, also known as the Gly40Ser variant of the GCGR) is associated with altered receptor function and has been linked to metabolic phenotypes in human genetic studies.

Biased Agonism at Class B GPCRs

G Protein versus β-Arrestin Signaling Bias

Like class A GPCRs, class B receptors signal through both G protein-dependent and β-arrestin-dependent pathways. The G_s-coupled receptors (GLP-1R, GIPR, GCGR) activate adenylyl cyclase, increasing intracellular cAMP, which mediates their primary physiological effects—insulin secretion (GLP-1R, GIPR) and hepatic glucose production (GCGR). Additionally, they can couple to G_q/G₁₁ (activating PLCβ and mobilizing intracellular Ca²⁺) and G_i/o (with lower efficiency). β-Arrestin recruitment to activated class B receptors mediates receptor desensitization and internalization, and also scaffolds β-arrestin-dependent signaling complexes that modulate ERK activation.

Biased agonism at class B receptors has been extensively characterized for the GLP-1R. Different GLP-1R agonists produce distinct cAMP and β-arrestin recruitment profiles. Exendin-4 is a balanced agonist with similar potency for cAMP production and β-arrestin recruitment. Certain oxyntomodulin-derived peptides show G protein bias with reduced β-arrestin recruitment. The physiological and therapeutic consequences of this bias are actively debated: G protein-biased GLP-1R agonists may produce more sustained cAMP signaling due to reduced receptor internalization (since β-arrestin is required for clathrin-mediated endocytosis), potentially translating into prolonged glycemic control. Conversely, β-arrestin-biased GLP-1R agonists may promote β-arrestin-dependent ERK signaling that could enhance β-cell proliferation and survival, effects that are desirable for preserving functional β-cell mass in diabetes.

Structural Basis of Biased Signaling

The structural basis for biased signaling at class B receptors is less well understood than for class A receptors, but several principles are emerging. Different peptide ligands induce subtly distinct TMD conformations that differentially expose G protein and β-arrestin coupling surfaces. The pattern of receptor phosphorylation by GRKs—the phosphorylation barcode—differs between agonists, influencing the conformation of the recruited β-arrestin. The ECD-bound peptide C-terminus can adopt different orientations that influence TMD conformation, providing a structural mechanism for the ECD to influence signaling bias.

Recent cryo-EM structures have begun to reveal these subtleties. Comparison of the GLP-1R in complex with GLP-1 vs exendin-4 vs biased peptide agonists shows differences in the TMD binding pocket geometry, particularly the positions of TM1, TM6, and TM7. These conformational differences are propagated to the intracellular G protein and β-arrestin coupling surfaces. For the GCGR, the antagonist MK-0893 and the partial agonist NNC1702 stabilize distinct TMD conformations that explain their different signaling profiles.

Quantifying Class B Receptor Bias

Bias quantification for class B receptors follows the operational model framework. Concentration-response curves for cAMP accumulation (G_s pathway) and β-arrestin recruitment are generated for a panel of agonists relative to a reference (typically the endogenous peptide hormone). Transduction coefficients (log(τ/K_A)) are extracted by fitting the operational model to the data. The bias factor is calculated as ΔΔlog(τ/K_A) between the two pathways. This method requires careful consideration of the experimental system: cell background, receptor expression level, and assay sensitivity all influence apparent bias, and normalization to a balanced reference agonist is essential to correct for system bias.

An alternative approach, used primarily in drug discovery, is the Δlog(E_max/EC₅₀) method, which does not require the full operational model fitting. However, this simpler method can produce inaccurate bias estimates when agonists have different \(E_{max}\) values and the system has significant receptor reserve. The "equiactive comparison" method, in which bias is assessed at equiactive concentrations of the agonists rather than from full concentration-response curves, provides a complementary approach that can reveal concentration-dependent bias (agonists that are biased at low concentrations but not at saturating concentrations).

GLP-1 Receptor Pharmacology

Endogenous Ligand and Physiology

GLP-1 is a 30-amino-acid peptide derived from tissue-specific post-translational processing of proglucagon in intestinal L-cells. The biologically active forms in humans are GLP-1(7–36)amide and GLP-1(7–37), both of which are equipotent at the GLP-1R. GLP-1 is secreted in response to nutrient ingestion, with plasma levels rising from a fasting baseline of 5–10 pM to peak postprandial levels of 15–50 pM. The peptide has an extraordinarily short plasma half-life (~2 minutes) owing to rapid N-terminal cleavage by DPP-4 (cleaving His7–Ala8) and renal clearance. DPP-4 cleavage generates GLP-1(9–36/37), which is either inactive or a weak antagonist at the GLP-1R.

GLP-1R is expressed in pancreatic β-cells (where it stimulates glucose-dependent insulin secretion), pancreatic α-cells (where it suppresses glucagon secretion), the central nervous system (hypothalamic nuclei involved in appetite regulation), the gastrointestinal tract (where it slows gastric emptying), the cardiovascular system, and the kidneys. This broad expression pattern explains the pleiotropic effects of GLP-1R agonists: improved glycemic control, weight loss, cardiovascular risk reduction, and potential renoprotective effects.

Therapeutic GLP-1 Receptor Agonists

The evolution of GLP-1R agonists illustrates the iterative application of peptide chemistry and pharmacology to transform a native peptide hormone with an unfavorable pharmacokinetic profile into blockbuster therapeutics.

First generation — exenatide (2005): Twice-daily injectable. The discovery that exendin-4, a naturally occurring GLP-1R agonist from Gila monster venom, is resistant to DPP-4 cleavage provided proof-of-concept that a peptide GLP-1R agonist could achieve therapeutic efficacy. Exenatide has ~50% sequence identity with human GLP-1 and a C-terminal extension (9 additional residues) that, together with the absence of the DPP-4 cleavage site (His7–Ala8 is replaced with His7–Gly8), provides moderate protease resistance. The C-terminal extension forms a Trp-cage motif that stabilizes the α-helical conformation.

Second generation — liraglutide (2010): Once-daily injectable. Liraglutide is a GLP-1 analog with a single amino acid substitution (Arg34 → Lys34) and a C16 fatty acid (palmitic acid) conjugated to Lys26 via a γ-glutamate spacer. The fatty acid moiety mediates reversible, high-affinity binding to serum albumin, which protects the peptide from DPP-4 cleavage and renal filtration, extending the plasma half-life to ~13 hours. The GLP-1 backbone retains 97% sequence identity with native GLP-1. Liraglutide was the first GLP-1R agonist to demonstrate cardiovascular benefit in a dedicated outcomes trial (LEADER, 2016).

Third generation — semaglutide (2017/2019): Once-weekly injectable and once-daily oral. Semaglutide is a further-optimized GLP-1 analog. Key modifications include: (1) substitution of Ala8 with α-aminoisobutyric acid (Aib) to provide complete DPP-4 resistance; (2) a C18 diacid (octadecanedioic acid) attached to Lys26 via a hydrophilic linker (γ-Glu–2× PEG) that enhances albumin binding affinity and prolongs half-life to ~165 hours (enabling once-weekly dosing); and (3) the linker chemistry improves solubility and reduces self-association, enabling the development of an oral formulation co-formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate).

Dual and triple agonists — tirzepatide and beyond: Tirzepatide (Mounjaro/Zepbound) is a 39-amino-acid linear peptide that functions as an imbalanced dual agonist at GLP-1R and GIPR. It incorporates Aib at position 2 and 13, a C20 diacid at Lys20, and a sequence designed to engage both receptors. At the GIPR, tirzepatide shows partial agonism for cAMP production (relative to native GIP) but full or supra-physiological activity at the GLP-1R. Recent cryo-EM structures of tirzepatide bound to both GLP-1R and GIPR have revealed the molecular basis for its dual receptor recognition. In Phase III trials (SURPASS program), tirzepatide achieved hemoglobin A1c reductions of up to 2.5% and weight loss of up to 22.5% in people with type 2 diabetes, results that exceeded those of semaglutide.

GIP Receptor Pharmacology

The GIPR was historically undervalued as a therapeutic target. GIP, a 42-amino-acid incretin secreted from duodenal K-cells, stimulates insulin secretion through the GIPR on β-cells. However, the insulinotropic effect of GIP is blunted in type 2 diabetes (a phenomenon termed "GIP resistance"), and GIP promotes glucagon secretion (potentially raising blood glucose), leading some investigators to question its therapeutic potential. The development of dual GLP-1/GIP receptor agonists was initially met with skepticism.

However, the demonstration that combining GIPR and GLP-1R agonism produces superior metabolic effects compared to either alone—a discovery made by Matthias Tschöp, Richard DiMarchi, and colleagues—revolutionized the field. The mechanism appears to involve: (1) GIPR agonism enhancing the insulinotropic effect of GLP-1R agonism through convergent signaling on the β-cell; (2) GIP acting centrally to enhance GLP-1-mediated appetite suppression and weight loss; and (3) GIP counteracting the gastrointestinal side effects (nausea, vomiting) of GLP-1R agonism by reducing neuronal activation in brainstem emetic centers. The cryo-EM structures of the GIPR (PDB: 7DTY) have provided a structural framework for rational design of dual agonists.

Glucagon Receptor Pharmacology

The GCGR is a class B receptor that presents both therapeutic opportunities and challenges. Glucagon, a 29-amino-acid peptide secreted from pancreatic α-cells, raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. GCGR antagonism lowers blood glucose and was explored as a diabetes therapy, but clinical development was limited by α-cell hyperplasia, increased liver enzymes, and elevated LDL-cholesterol.

The concept of combining GCGR agonism with GLP-1R agonism in a single peptide emerged from the recognition that glucagon promotes energy expenditure and lipolysis (favorable for weight loss), while GLP-1 counteracts the hyperglycemic effects of glucagon by stimulating insulin secretion. Triple GLP-1/GIP/glucagon receptor agonists (such as retatrutide, LY3437943) are now in late-stage clinical development and have shown unprecedented weight loss (up to 24% at 48 weeks in Phase II trials) through the combined mechanisms of appetite suppression, increased energy expenditure, and improved insulin secretion.

Therapeutic Peptide Design Principles

The design of therapeutic peptides targeting class B receptors involves balancing multiple competing objectives: high potency at the target receptor(s), selectivity versus related receptors, a desirable signaling bias profile, extended plasma half-life, physicochemical stability, and manufacturability. Key design principles that have emerged from two decades of intensive research include:

Backbone stabilization: Substitution of DPP-4-cleavable residues with non-natural amino acids (e.g., Aib for Ala8) provides protease resistance. N-terminal modifications including N-methylation, cyclization, or incorporation of β-amino acids further enhance stability. The α-helical structure of the peptide C-terminal region, which is critical for ECD binding, can be stabilized by helix-promoting substitutions (e.g., replacing Gly with Ala at helix-permissive positions), introduction of salt bridges (\(i\), \(i\)+4 Glu–Lys pairs), or lactam bridges between side chains.

Half-life extension through albumin binding: Conjugation of fatty acids (C14–C20) to specific positions in the peptide sequence via hydrophilic linkers is the most successful strategy for extending class B peptide half-life. The fatty acid–albumin interaction provides a depot effect: the albumin-bound peptide is protected from proteolysis and renal clearance, and dissociation from albumin releases active peptide. The linker chemistry (γ-Glu, PEG, mini-PEG) influences albumin binding affinity, peptide solubility, and self-association. The fatty acid position must be carefully chosen to avoid disrupting receptor binding—Lys26 has proven to be an optimal conjugation site for GLP-1 analogs.

Fc fusion and PEGylation: Alternative half-life extension strategies include genetic fusion to the Fc domain of immunoglobulin G (dulaglutide, a GLP-1–Fc fusion protein with once-weekly dosing) and PEGylation (though PEGylated GLP-1 analogs have been largely superseded by fatty acid conjugation due to concerns about PEG immunogenicity and accumulation).

Oral peptide delivery: The development of oral semaglutide established that peptide therapeutics for class B receptors can achieve clinically meaningful oral bioavailability when co-formulated with absorption enhancers. SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) transiently increases gastric epithelial permeability by modulating tight junctions and buffers the local pH to protect the peptide from gastric acid and pepsin-mediated degradation. Oral semaglutide achieves a bioavailability of approximately 0.8–1.0%—low in absolute terms, but sufficient for therapeutic efficacy with appropriate dosing (7–14 mg daily). This breakthrough has stimulated research into other oral peptide delivery technologies.

Multi-receptor agonism: The design of peptides that simultaneously activate two or three class B receptors represents the current frontier. Sequence alignment and structural superimposition guide the design of "chimeric" sequences that incorporate key pharmacophoric elements from multiple native peptides. Computational modeling and molecular dynamics simulations are used to predict receptor engagement. The resulting peptides typically show "imbalanced" agonism—different relative activities at the different receptors—which is achieved by tuning the proportion of receptor-specific pharmacophoric elements in the sequence. The optimal balance of activities is determined empirically through iterative design and testing in cellular assays, animal models, and ultimately human clinical trials.

Research Evidence

Finding	Data	Source
GLP-1R–GLP-1–Gs complex — two-domain binding with ECD capture and TMD engagement	Cryo-EM at 3.3 Å	Liang et al., Nature 2018; 555:121–125
Exendin-4 structure — Trp-cage C-terminal motif stabilizes bioactive α-helix	NMR, 2.2 Å	Neidigh et al., Biochemistry 2001; 40:13188–13200
GLP-1R ECD–GLP-1(15–35) complex — peptide C-terminal helix docks into hydrophobic groove	X-ray crystallography at 2.1 Å	Underwood et al., J Biol Chem 2010; 285:723–730
Semaglutide — Aib substitution provides DPP-4 resistance, C18 diacid enables once-weekly dosing	SPR, PK in minipigs	Lau et al., J Med Chem 2015; 58:7370–7380
Tirzepatide GLP-1R/GIPR dual agonism — imbalanced signaling with superior weight loss vs semaglutide	SURPASS-2 Phase III RCT	Frías et al., N Engl J Med 2021; 385:503–515
Liraglutide cardiovascular outcomes — 13% reduction in MACE (LEADER trial)	Randomized, double-blind, placebo-controlled	Marso et al., N Engl J Med 2016; 375:311–322
Oral semaglutide with SNAC — 0.8–1.0% bioavailability, non-inferior to injectable semaglutide	PIONEER Phase III program	Davies et al., JAMA 2017; 318:1460–1470
GCGR cryo-EM structures — activation mechanism and antagonist binding modes	Cryo-EM at 3.0–3.2 Å	Zhang et al., Nature 2018; 553:91–95
GIPR cryo-EM — structural basis for incretin receptor recognition	Cryo-EM at 3.1 Å	Zhao et al., Nat Struct Mol Biol 2022; 29:34–43
Biased GLP-1R agonists — reduced β-arrestin recruitment prolongs cAMP signaling	BRET, pERK, cAMP assays	Wootten et al., Mol Pharmacol 2013; 83:822–834
Triple GLP-1/GIP/glucagon agonist retatrutide — 24.2% weight loss at 48 weeks	Randomized Phase II trial	Jastreboff et al., N Engl J Med 2023; 389:514–526
GLP-1R negative allosteric modulation by PF-06372222 — cooperativity factor α = 0.02	Radioligand binding, functional	Song et al., J Biol Chem 2015; 290:20200–20210

FAQ

**What distinguishes class B GPCRs from class A GPCRs structurally?** Class B GPCRs are distinguished by their large N-terminal extracellular domain (ECD, ~120–150 amino acids) that forms a structurally conserved fold stabilized by three disulfide bonds. This ECD is the primary determinant of peptide hormone binding affinity, whereas in class A peptide receptors, the ligand typically binds entirely within the transmembrane domain. The TMD of class B receptors has a more open, solvent-exposed binding pocket to accommodate the peptide N-terminus that engages the TMD after ECD capture. Class B receptors also lack the conserved D(E)RY, CWxP, and NPxxY motifs found in class A receptors, possessing instead class-specific signaling motifs such as the HET motif in TM2 and the PxxG hinge in TM6.

**How does the two-domain binding mechanism work for class B GPCRs?** The two-domain mechanism proceeds in two steps: (1) The C-terminal α-helical region of the peptide hormone binds to the hydrophobic groove on the receptor ECD with moderate affinity ($K_d \sim 0.1$–1 μM for the isolated ECD). This capture step positions the peptide N-terminus for productive engagement with the TMD. (2) The N-terminal region of the peptide (residues 1–10) inserts into the TMD binding pocket and makes critical contacts with residues in TM1, TM2, TM3, TM5, TM6, and TM7. These TMD contacts drive the conformational changes that lead to G protein coupling and receptor activation. The ECD capture dramatically increases the effective concentration of the peptide N-terminus at the TMD entrance, enabling activation at nanomolar peptide concentrations.

**Why is native GLP-1 unsuitable as a therapeutic agent?** Native GLP-1 has an extremely short plasma half-life of approximately 2 minutes, making it impractical as a therapeutic. This rapid clearance is due to two mechanisms: (1) N-terminal cleavage between His7 and Ala8 by dipeptidyl peptidase-4 (DPP-4), which inactivates the peptide; and (2) rapid renal clearance of the small peptide (~3.3 kDa, below the glomerular filtration threshold of ~60 kDa). Additionally, GLP-1 in solution is prone to physical instability (aggregation and fibrillation) at pharmaceutical concentrations. Therapeutic GLP-1 receptor agonists address these limitations through structural modifications—non-natural amino acids at the DPP-4 cleavage site (e.g., Aib⁸ in semaglutide) and half-life extension strategies (fatty acid conjugation, Fc fusion, PEGylation) that promote albumin binding and reduce renal clearance.

**How does semaglutide achieve once-weekly dosing?** Semaglutide achieves its ~165-hour half-life through three key design features: (1) The Aib (α-aminoisobutyric acid) substitution at position 8 provides complete resistance to DPP-4 cleavage. (2) A C18 fatty diacid (octadecanedioic acid) is conjugated to Lys26 via a hydrophilic linker (γ-Glu–2× PEG), enabling high-affinity, reversible binding to serum albumin. Albumin binding protects semaglutide from proteolytic degradation and renal clearance, creating a circulating depot from which active peptide slowly dissociates. (3) The hydrophilic linker enhances solubility and reduces self-association compared to liraglutide, minimizing injection-site reactions and improving pharmacokinetic consistency. The combination of these features provides a steady-state trough concentration above the therapeutic threshold with once-weekly subcutaneous administration.

**What is tirzepatide and how does it differ from selective GLP-1R agonists?** Tirzepatide (Mounjaro/Zepbound) is a synthetic 39-amino-acid linear peptide that acts as an imbalanced dual agonist at both GLP-1R and GIPR. Unlike selective GLP-1R agonists (semaglutide, liraglutide), tirzepatide also activates the GIP receptor—a feature that was initially counterintuitive because GIP was thought to worsen glucose control in type 2 diabetes. However, GIPR activation in the presence of GLP-1R agonism enhances insulin secretion, promotes additional weight loss through central mechanisms, and reduces GI side effects. Tirzepatide achieves superior glycemic control (HbA1c reduction up to 2.5%) and weight loss (up to 22.5%) compared to semaglutide in head-to-head trials, establishing dual incretin agonism as a new paradigm in metabolic disease therapy.

**What is the role of biased agonism at class B receptors?** Biased agonism at class B receptors describes the ability of different peptide agonists to preferentially activate G protein-mediated signaling (cAMP production) versus β-arrestin-mediated signaling (receptor internalization, β-arrestin-dependent ERK activation) through the same receptor. G protein-biased GLP-1R agonists may produce more sustained cAMP signaling because reduced β-arrestin recruitment impairs receptor internalization and desensitization, potentially extending the duration of glycemic control. Conversely, balanced or β-arrestin-biased agonists may promote β-arrestin-dependent signaling pathways that enhance β-cell survival. The therapeutic relevance of biased agonism for class B receptors is an active area of investigation, with biased agonists in preclinical and early clinical development.

**How are oral peptide formulations for class B receptors achieved?** Oral peptide delivery for class B receptors, exemplified by oral semaglutide, uses absorption enhancers to overcome the formidable barriers to oral peptide absorption. The SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) molecule facilitates absorption through multiple mechanisms: (1) it transiently increases gastric epithelial permeability by modulating tight junction proteins; (2) it buffers the local microenvironment to a pH (~5–6) that protects semaglutide from gastric acid and pepsin-mediated degradation; (3) it promotes peptide monomerization, reducing the aggregation that impedes absorption. Despite achieving only ~0.8–1.0% oral bioavailability, the high potency of semaglutide enables therapeutic efficacy with daily 7–14 mg oral doses. Alternative technologies including permeation enhancers, mucoadhesive formulations, and nanoparticle carriers are under investigation.

**What are triple agonists and why are they being developed?** Triple agonists are single peptide molecules that simultaneously activate GLP-1R, GIPR, and GCGR. The rationale is that combining the complementary metabolic effects of all three receptors—GLP-1R-mediated insulin secretion, satiety, and glucose lowering; GIPR-mediated enhancement of insulin secretion and metabolic efficiency; and GCGR-mediated energy expenditure and lipolysis—could produce superior weight loss and metabolic benefits compared to single or dual agonists. The GLP-1 component additionally counteracts the hyperglycemic potential of GCGR activation. Retatrutide (LY3437943), the most advanced triple agonist, achieved 24.2% mean weight loss at 48 weeks in a Phase II trial, representing the highest weight loss reported for any pharmacotherapy to date. Triple agonists are now among the most promising candidates in the metabolic drug development pipeline.

**How does the ECD contribute to ligand selectivity among class B receptors?** The ECD is a major determinant of ligand selectivity. Despite high structural similarity, the ECDs of GLP-1R, GIPR, and GCGR display sequence variations in the peptide-binding groove that determine which peptide hormones are recognized. The GLP-1R ECD binds GLP-1 with ~10-fold higher affinity than glucagon, while the GCGR ECD shows the reciprocal preference. Key selectivity-determining residues map to the β-sheet surface and flanking loop regions of the ECD. Domain-swapping experiments—replacing the GLP-1R ECD with the GCGR ECD, and vice versa—swap the ligand selectivity accordingly. The ECD also influences the positioning of the peptide N-terminus for TMD engagement, contributing to both affinity and efficacy selectivity.

**What is the significance of the LEADER trial for GLP-1 receptor agonists?** The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results, 2016) was a landmark cardiovascular outcomes trial that demonstrated for the first time that a GLP-1 receptor agonist reduces major adverse cardiovascular events (MACE). In 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 13% (HR 0.87, p = 0.01) and reduced cardiovascular death by 22% (HR 0.78, p = 0.007) compared to placebo, both on background standard-of-care therapy. This trial transformed the clinical positioning of GLP-1R agonists from glucose-lowering agents to cardioprotective therapies and established cardiovascular outcomes trials as a requirement for new diabetes drugs. Subsequent trials confirmed cardiovascular benefits for semaglutide (SUSTAIN-6), dulaglutide (REWIND), and other GLP-1R agonists.

What Is Established

• Class B GPCRs share a two-domain architecture — a conserved 120–150-residue extracellular domain plus a seven-transmembrane domain — and activate through a two-step mechanism: C-terminal peptide docking onto the ECD followed by N-terminal engagement of the TMD.
• GLP-1 signals through Gs/cAMP to potentiate glucose-dependent insulin secretion; native GLP-1's ~2-minute half-life reflects DPP-4 cleavage and renal clearance, and therapeutic analogs overcome both.
• Structure-guided chemistry yields long-acting agonists: Aib substitution plus C18 diacid albumin binding give semaglutide a ~165-hour half-life, and SNAC-enabled oral absorption achieves ~0.8–1.0% bioavailability, sufficient for therapeutic efficacy.
• Multi-receptor co-agonism outperforms single-receptor agonism in trials: tirzepatide (GLP-1/GIP) achieved superior glycemic and weight outcomes versus semaglutide, and retatrutide (GLP-1/GIP/glucagon) produced ~24% weight loss at 48 weeks in a Phase II study.
• Cardiovascular benefit has been documented for a GLP-1 receptor agonist (liraglutide in LEADER), extending class B peptide pharmacology beyond glycemic control.

What Remains Uncertain

• Whether G protein bias versus β-arrestin engagement at class B receptors translates into clinical advantage — the physiological and therapeutic consequences of biased agonism are actively debated.
• The structural basis of biased signaling at class B receptors is less well understood than for class A; how ECD orientation, TMD conformational nuance, and phosphorylation barcodes encode pathway selection is incompletely mapped.
• The optimal balance of receptor activities in multi-agonists is set empirically through iterative design and testing rather than by predictive rules.
• Whether oral peptide delivery strategies generalize beyond the SNAC-enabled semaglutide formulation as other technologies are explored.

Research Gaps

• Comparative analyses linking receptor-level signaling profiles (bias, kinetics, engagement geometry) to clinical performance across class B agonists are limited; most comparisons stop at potency and efficacy ratios.
• Structural characterization across class B family members with different transducer partners remains incomplete, restricting generalizable design rules for pathway-selective ligands.
• Bias measurements remain sensitive to cell background, receptor expression level, and assay sensitivity, and cross-study standardization is incomplete.

Key References

• Liang YL, Khoshouei M, Glukhova A, et al. (2018). Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor–Gs complex. Nature 555(7695):121–125. doi:10.1038/nature25773 — shows how a biased agonist reshapes the active GLP-1R–Gs complex.
• Underwood CR, Garibay P, Knudsen LB, et al. (2010). Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. Journal of Biological Chemistry 285(1):723–730. doi:10.1074/jbc.M109.033829 — defines ECD capture, the first step of the two-domain binding mechanism.
• Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry 58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726 — documents the chemistry that extended GLP-1 pharmacology to once-weekly dosing.
• Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine 385(6):503–515. doi:10.1056/NEJMoa2107519 — head-to-head human evidence that dual GLP-1/GIP agonism exceeds selective GLP-1R agonism.
• Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine 389(6):514–526. doi:10.1056/NEJMoa2301972 — carries multi-receptor class B pharmacology into the triple-agonist frontier.

Related Data

• Tirzepatide Technical Manual — documentation for the dual GLP-1/GIP co-agonist discussed in this article's pharmacology sections.
• Retatrutide Technical Manual — documentation for the triple GLP-1/GIP/glucagon agonist at the frontier of multi-receptor design.

References

1. Liang YL, Khoshouei M, Glukhova A, et al. Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor–Gs complex. Nature. 2018;555(7695):121–125. doi:10.1038/nature25773
2. Underwood CR, Garibay P, Knudsen LB, et al. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem. 2010;285(1):723–730. doi:10.1074/jbc.M109.033829
3. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
5. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
6. Zhang H, Qiao A, Yang D, et al. Structure of the full-length glucagon class B G-protein-coupled receptor. Nature. 2017;546(7657):259–264. doi:10.1038/nature22363
7. Zhao P, Liang YL, Belousoff MJ, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020;577(7790):432–436. doi:10.1038/s41586-019-1902-z
8. Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci USA. 2013;110(13):5211–5216. doi:10.1073/pnas.1220672110
9. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
10. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157. doi:10.1053/j.gastro.2007.03.054
11. Pal K, Melcher K, Xu HE. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors. Acta Pharmacol Sin. 2012;33(3):300–311. doi:10.1038/aps.2011.170
12. Hollenstein K, Kean J, Bortolato A, et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature. 2013;499(7459):438–443. doi:10.1038/nature12357
13. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27–36. doi:10.1038/nm.3761
14. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155
15. Graaf C, Donnelly D, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954–1013. doi:10.1124/pr.115.011395